Drug Trial Radar · NCT04542824
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
78
Actual
Start
Aug 20, 2020
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Sep 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior standard of care (SOC). The trial consists of two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2). The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese participants with relapsed, progressive or refractory B-cell lymphoma and Japanese participants with B-cell lymphomas that have achieved PR or CR. In the expansion part, additional participants will be treated with epcoritamab, at the RP2D and the purpose is to further explore and determine the safety and efficacy of epcoritamab. Part 2 of the trial will be initiated once the RP2D has been determined in Part 1. In Part 2, epcoritamab is investigated as a monotherapy and in combination with other SOC agents.
Conditions
- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Small Lymphocytic Lymphoma
Interventions
Epcoritamab (monotherapy)Biological
Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
EpcoritamabBiological
Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneDrug
21-day cycles
Gemcitabine and oxaliplatinDrug
28-day cycles
Epcoritamab (maintenance)Biological
28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
Rituximab and lenalidomideDrug
28-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years
- Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: DLTs are assessed during the first cycle (28 days) in each cohort
- Part 2, Arm 1: Objective Response Rate (ORR)Time frame: Up to 1.5 years
- Part 2, Arms 2-4: Number of Participants with DLTsTime frame: DLTs are assessed during the first cycle (28 days) in arms 2-4
- Part 2, Arms 2-5: Number of Participants with TEAEsTime frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Aichi Cancer Center Hospital
Aichi, Japan
NHO Nagoya Medical Center
Aichi, Japan
National Cancer Center Hospital East
Chiba, Japan
Matsuyama Red Cross Hospital
Ehime, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
Fukushima Medical University Hospital
Fukushima, Japan
Kagoshima University Hospital
Kagoshima, Japan
Kyoto University Hospital
Kyoto, Japan
Kindai University Hospital
Osaka, Japan
Osaka University Hospital
Osaka, Japan
Cancer Institute Hospital of JFCR
Tokyo, Japan
National Cancer Center Hospital
Tokyo, Japan
Tokyo Medical University Hospital
Tokyo, Japan
Yamagata University Hospital
Yamagata, Japan
Tohoku University Hoaspital
Sendai, Miyagi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.